Details for New Drug Application (NDA): 010721
✉ Email this page to a colleague
The generic ingredient in ANTIVERT is meclizine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the meclizine hydrochloride profile page.
Summary for 010721
| Tradename: | ANTIVERT |
| Applicant: | Casper Pharma Llc |
| Ingredient: | meclizine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 010721
Suppliers and Packaging for NDA: 010721
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ANTIVERT | meclizine hydrochloride | TABLET, CHEWABLE;ORAL | 010721 | NDA AUTHORIZED GENERIC | Rising Pharma Holdings, Inc. | 16571-660 | 16571-660-01 | 100 TABLET in 1 BOTTLE (16571-660-01) |
| ANTIVERT | meclizine hydrochloride | TABLET, CHEWABLE;ORAL | 010721 | NDA AUTHORIZED GENERIC | Rising Pharma Holdings, Inc. | 16571-660 | 16571-660-50 | 500 TABLET in 1 BOTTLE (16571-660-50) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Jan 20, 1982 | TE: | AA | RLD: | Yes | ||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AA | RLD: | Yes | ||||
Profile for product number 005
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, CHEWABLE;ORAL | Strength | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
